DOse REduction of preoperatieve radiotherapyin MYxoid liposarcoma.(Dosis verlaging van de preoperatieve bestraling van myxoidliposarcomen).

• Conditions: radiotherapy, myxoid liposarcoma, soft tissue sarcoma (radiotherapie, myxoid sarcomm en weke delen sarcoom)

• Registration Number: NL-OMON23428
• Lead Sponsor: KI-AV

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

1. Age >18 years;

2. By biopsy proven myxoid sarcoma;

Exclusion Criteria

1. Prior radiotherapy to target area;

2. Anticoagulant medication of any kind; especially Ascal (and derivates), coumarines, all heparin and heparin-like formulations;

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The dose reduction will be regarded as a success if at least 90% of thus treated patients show at least 90% necrosis in the definitive resection specimen.

Secondary Outcome Measures

Name	Time	Method
The aim is to provide a stopping rule for inefficacy of the new dose.